The reactivation of silent but intact copies of these tumor suppressors with agents such as 5-aza-2′-deoxycytidine and histone deacetylase (HDAC) inhibitors such as trichostatin has been proposed as a strategy to enhance therapeutic responses in solid tumors. This evidence concerns the gene HDAC9 and neoplasm.